Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and other institutions have shown that a molecule developed by Stemsynergy Therapeutics (SSTC3) controls the progression of colorectal cancer in several cell lines and human tumor xenografts. SSTC3 modulates the WNT pathway but does not show the on-target toxicity normally associated with WNT inhibitors.
In 2014, Donna Robinson had a routine colonoscopy. During the procedure, the physician detected a small mass. Two days later, on her 58th birthday, she received the bad news. The small mass was actually part of a very large mass that had grown through the wall of her intestine and into other locations in her abdomen. It was locally advanced pancreatic cancer, she was told — inoperable and incurable.
Marcela Vieira couldn’t believe that cancer kept coming back. Her first bout was with breast cancer in 2002, when she was only 36. It returned in 2010. In 2013, she was diagnosed with ovarian cancer. It also returned, in 2014. “At first you don’t believe it, and you ask, ‘Why me?’” she said.
Donald Kumin doesn’t look like someone who has cancer. The vibrant 88-year-old Delray Beach resident regularly plays golf with friends. He and his wife, Irene, are taking a cruise this fall, and at an age when many of their contemporaries have gone into assisted living, they are proud to be leading an active life from their own home.
Six physician-scientists were recognized for their contributions to cancer research and treatment as part of the Sylvester Comprehensive Cancer Center’s 18th Annual Zubrod Memorial Lecture and Sylvester Cancer Research Poster Session on May 19. Sylvester Director Stephen D. Nimer, M.D., hosted the event.
Maria Figueroa, M.D., a researcher at Sylvester Comprehensive Cancer Center and associate professor of human genetics at the University of Miami Miller School of Medicine, published a paper in the journal Cancer Discovery that provides new insights into how certain molecular pathways influence acute myeloid leukemia (AML).
Sylvester Comprehensive Cancer Center and the DeWitt Daughtry Family Department of Surgery at the University of Miami Miller School of Medicine hosted the inaugural surgery research day and Lily Altschuler Memorial Symposium in Pancreatic Cancer Research on May 12, showcasing scientific achievements of faculty and trainees.
Sylvester Comprehensive Cancer Center and the University of Miami Miller School of Medicine recently signed a memorandum of understanding with the Dominican Republic’s Instituto de Oncologia Dr. Heriberto Pieter. The agreement allows Miller School oncology experts to provide their evidence-based expertise to improve cancer care, research and clinical trial initiatives and health outcomes in the Dominican Republic.
For years, a protein called vascular endothelial growth factor (VEGF) has been known for its ability to generate new blood vessels. As tumors grow, and need more oxygen and nutrients, they secrete VEGF to increase their blood supply. That was a radical discovery 20 years ago, and some believed it would create many therapeutic opportunities against cancer.
Researchers are trying to figure out why changes in the interactions of proteins can cause cancer. Stephen D. Nimer, M.D., director of Sylvester Comprehensive Cancer Center, was co-senior author on a paper, published in the journal PNAS, that describes how the protein DPF2 regulates blood production. High levels of DPF2 are seen in patients with acute myelogenous leukemia (AML).